Insider Selling: Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Insider Sells $675,532.00 in Stock

Chemomab Therapeutics Ltd. (NASDAQ:CMMBGet Rating) insider George Adi Mor sold 324,775 shares of Chemomab Therapeutics stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $2.08, for a total value of $675,532.00. Following the transaction, the insider now owns 324,775 shares in the company, valued at approximately $675,532. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Chemomab Therapeutics Price Performance

NASDAQ:CMMB opened at $2.09 on Friday. The stock has a market cap of $23.89 million, a PE ratio of -0.99 and a beta of 0.65. Chemomab Therapeutics Ltd. has a fifty-two week low of $1.75 and a fifty-two week high of $9.96. The stock’s 50-day moving average is $2.31 and its two-hundred day moving average is $2.97.

Hedge Funds Weigh In On Chemomab Therapeutics

A number of large investors have recently made changes to their positions in the business. Envestnet Asset Management Inc. acquired a new position in shares of Chemomab Therapeutics in the 1st quarter valued at about $52,000. Citadel Advisors LLC acquired a new position in shares of Chemomab Therapeutics in the 3rd quarter valued at about $53,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Chemomab Therapeutics in the 1st quarter valued at about $134,000. Institutional investors and hedge funds own 28.87% of the company’s stock.

About Chemomab Therapeutics

(Get Rating)

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Further Reading

Insider Buying and Selling by Quarter for Chemomab Therapeutics (NASDAQ:CMMB)

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.